Patent Application
20130109870
The present invention relates to the Amorphous Form of 4-acetoxy-2α-benzoyloxy-5β-20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotan-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate, i.e Cabazitaxel, methods for its preparation and pharmaceutical composition thereof.
Cabazitaxel, chemically known as 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotax-11-en-13α-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate, is represented by formula (I).
It is a microtubule inhibitor, indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen, under the trade name Jevtana®.
Cabazitaxel is known from U.S. Pat. No. 5,847,170. Process for preparation of Cabazitaxel as described in U.S. Pat. No. 5,847,170 involves column chromatography, which is cumbersome tedious and not commercially viable.
The acetone solvate of 4-acetoxy-2α-benzoyloxy-5β-20-epoxy-1-hydroxy-7β, 10β-dimethoxy-9-oxotan-11-en-13α-yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (Form A) is formed by crystallization by using acetone and is characterized by XRD in U.S. Pat. No. 7,241,907.
U.S. 20110144362 describes anhydrous crystalline Forms B to Form F, ethanolates Form B, D, E and F and mono and dihydrate Forms of Cabazitaxel. All the anhydrous crystalline forms are prepared either by acetone solvate or ethanol solvate. Mono and dihydrate forms are formed at ambient temperature in an atmosphere containing 10 and 60% relative humidity, respectively.
From the above mentioned references it is evident that pure polymorphic form of Cabazitaxel prepared in the literature has been prepared by solvates and not directly from Cabazitaxel.
None of literature reported earlier mentions about the Amorphous form of Cabazitaxel. Present invention provides novel form of Cabazitaxel i.e. Amorphous
Cabazitaxel obtained, which is directly obtained from the crude Cabazitaxel without formation of any solvate or hydrate of Cabazitaxel.
In the first aspect, there is provided an Amorphous form of Cabazitaxel.
In the second aspect, there is provided a process for preparation of Amorphous form of Cabazitaxel comprising the steps of:
In another aspect, there is provided a pharmaceutical composition that includes a therapeutically effective amount of an Amorphous form of Cabazitaxel and one or more Pharmaceutically acceptable carriers, excipients or diluents.
The Amorphous form of Cabazitaxel may be characterized by XRD as depicted in FIG.-1.
The Amorphous form of Cabazitaxel is totally and completely devoid of any signal due to a crystalline form, in its X-ray (powder) diffraction pattern.
4-acetoxy-2α-benzoyloxy-5β-20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotan-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate i.e., Cabazitaxel used as starting material, may be prepared according to the method known in art such as described in U.S. Pat. No. 5,847,170.
In general, the solution of Cabazitaxel may be obtained by dissolving Cabazitaxel in suitable Solvent.
The suitable solvent may be selected from the group comprising of alcohols, such as methanol, ethanol and isopropanol; nitriles, such as acetonitrile; chlorinated hydrocarbons, such as methylene chloride, ethylene dichloride; esters, such as ethyl acetate and isopropyl acetate; cyclic ethers, such as dioxane and tetrahydrofuran and mixtures thereof. Most preferred solvent is methylene chloride.
The volume of the solvent, that can be used in step a) depends on the polarity and the solubilizing capacity of the solvent and typically can be employed in the range of between 2 to 100 times by volume per gram of Cabazitaxel.
The solution of Cabazitaxel in suitable solvent may be obtained at ambient temperature.
Removal of solvent may include one or more distillation, distillation under vacuum, evaporation, spray drying and freeze drying.
The temperature at which the solvent is removed depends on the solvent employed and generally can be from about 20° C. to about 200° C.
After evaporation of the solvent, the residual solid may optionally be treated with an organic solvent. Organic solvent may be selected from the hydrocarbon such as hexane, heptane, toluene and benzene.
The Amorphous form of Cabazitaxel may be recovered from the solution using a spray drying technique. A mini-Spray dryer (Model: Labultima (LU228) can be used. Labultima (LU228) Mini-Spray Dryer operates on the principle of nozzle spraying in a parallel flow, i.e the sprayed product and the drying gas flow in the same direction. The drying gas can be air or inert gases such as nitrogen, argon and carbon dioxide.
The air inlet temperature of the spray drier can be from about 40° C. to about 100° C.
After removal of the solvent the process may include drying of the residual solid in a drying oven.
The resulting Amorphous form of Cabazitaxel may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. In these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients. In addition to the common dosage forms set out above, the Amorphous form of Cabazitaxel may also be administered by controlled release means and/or delivery devices.
Further, the Amorphous Cabazitaxel described herein can be used in a method for treatment of hormone-refractory metastatic prostate cancer. The method of treatment includes administering to a mammal in need of treatment a dosage form that includes a therapeutically effective amount of the Amorphous form of Cabazitaxel.
The methods for the preparation of the Amorphous Form of Cabazitaxel of the present invention may be illustrated by way of the following examples, which in no way should be construed as limiting the scope of the invention.
2.0 g of Cabazitaxel was dissolved in 20 ml of Dichloromethane and concentrated at 35-40° C. under vacuum to get solid product. Product was further dried for 1 h at 35-40° C. under vacuum. Crude product was stirred with 40 ml n-Hexane at room temperature for 15-20 min and filtered. Obtained solid material was washed with 40 ml n-Hexane and dried for 6-7 hrs at 50-55° C. under reduced pressure.
2.0 g of Cabazitaxel was dissolved in 20 ml of Dichloromethane. The solution was then filtered through 0.5 micron filter and filtrate was spray dried for 6 hrs at 40-45° C. to get Amorphous Cabazitaxel.
| Number | Date | Country | Kind |
|---|---|---|---|
| 3109/DEL/2011 | Nov 2011 | IN | national |
